Hormone Replacement Therapy and Glycemic Control: Evidence from Observational Studies and Randomized Clinical Trials
暂无分享,去创建一个
[1] W. Sutherland,et al. The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes: a randomized controlled trial. , 2001, Archives of internal medicine.
[2] Jennifer Y. Liu,et al. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: The Northern California Kaiser Permanente Diabetes Registry. , 2001, Diabetes care.
[3] J. Connell,et al. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. , 2001, The Journal of clinical endocrinology and metabolism.
[4] K. Friday,et al. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.
[5] C. Aguilar-Salinas,et al. Effects of estrogen/medrogestone therapy on the apoprotein B-containing lipoproteins in postmenopausal women with type 2 diabetes mellitus under satisfactory and non-satisfactory glycemic control. , 2001, The Israel Medical Association journal : IMAJ.
[6] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[7] M. Frölich,et al. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM , 1997, Diabetologia.
[8] P. Björntorp,et al. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.
[9] Susan R. Johnson,et al. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .
[10] B. Walsh,et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women , 1994, Obstetrics and gynecology.